Why IceCure Medical Ltd’s (ICCM) Stock Is Down 7.67%
As of Friday, October 10, IceCure Medical Ltd’s ICCM share price has dipped by 7.67%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.
Commentary & Analysis
Why IceCure Medical Ltd’s (ICCM) Stock Is Up 5.81%
As of Monday, October 06, IceCure Medical Ltd’s ICCM share price has surged by 5.81%, which has investors questioning if this is right time to sell.Jenna Brashear
Why IceCure Medical Ltd’s (ICCM) Stock Is Up 7.05%
As of Monday, September 15, IceCure Medical Ltd’s ICCM share price has surged by 7.05%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why IceCure Medical Ltd’s (ICCM) Stock Is Down 6.87%
As of Tuesday, September 02, IceCure Medical Ltd’s ICCM share price has dipped by 6.87%, which has investors questioning if this is right time to buy.Jenna Brashear
Why IceCure Medical Ltd’s (ICCM) Stock Is Down 7.55%
As of Friday, August 29, IceCure Medical Ltd’s ICCM share price has dipped by 7.55%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ICCM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5.1 | $385.5 | 4% |
|
| Shares Out (Mil) | 3.1 | 40.8 | 11% |
|
| Institutional Ownership | 9.7% | 83.0% | 6% |
|
| Float (Mil) | 3.4 | 35.5 | 9% |
|
| Beta | 0.45 | 0.85 | 25% |
|
| Avg Daily Volume (000s) | 258 | 321 | 48% |
|
| Price Change (52-week) |
(96.3%) | 64.6% | 3% |
|
| Growth | ICCM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (2.7%) | 11.8% | 12% |
|
| Net Income (5yr) | (32.5%) | (5.5%) | 12% |
|
| EPS (5yr) | (1.7%) | 10.2% | 29 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 16.6% | (15.5%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 2 | |
| Current EPS | ($0.830) | ($4.610) | ($3.305) | |
| Month Ago EPS | ($0.830) | ($4.610) | ($3.305) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.880) | ($4.755) | ($2.510) | |
| Year/Year Chg | (43.1%) | (35.1%) | (69.3%) | |
| Financials | ICCM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4 | $155 | 5% |
|
| Net Income (TTM) (Mil) | ($17) | ($9) | 25% |
|
| EPS (TTM) | ($6.659) | ($0.400) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($16) | ($2) | 17% |
|
| Net Cash Flow (TTM) (Mil) | $4 | $1 | 51% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $27 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($5) | $418 | 2% |
|
| Valuation | ICCM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.32 | 2.69 | 5% |
|
| P/E | na | 24.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | ICCM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 36.1% | 58.5% | 44% |
|
| Net Margin | (427.7%) | (6.9%) | 2% |
|
| ROA | (102.1%) | (12.2%) | 5% |
|
| ROE | (150.0%) | (10.5%) | 6% |
|
| Liabilities to Assets | 32.8% | 47.2% | 24% |
|
| F-Score | 3 | 4 | 18% |
|
Passing Stock Screens
As of 10/9/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Schloss Screen
Factors: Value, Quality
This screen looks for stocks hitting new lows, trading at a price lower than book value per share, with no debt and high levels of insider ownership.
| Performance Since Inception: | 3.6% |
| +/- S&P 500: | -3.9 |
